Guardant Health stock hits 52-week high at 53.49 USD

Guardant Health Inc (NASDAQ:GH) stock has reached a new 52-week high, hitting 53.49 USD, with an impressive 8.81% gain just this past week. According to InvestingPro data, the company commands a market capitalization of $6.56 billion. This milestone reflects a significant upward trajectory for the company, marking a notable recovery and growth in its market performance. The company has demonstrated strong revenue growth of 28.74% and maintains a healthy liquidity position with a current ratio of 3.71. While the stock has experienced a substantial increase of 47.31% over the past year, InvestingPro analysis suggests the stock is currently trading above its Fair Value. Discover 12+ additional exclusive insights and detailed financial metrics with an InvestingPro subscription. This achievement highlights Guardant Health’s resilience and potential for continued growth in the competitive landscape of medical diagnostics and cancer detection, with analysts maintaining a bullish outlook on the stock. A comprehensive analysis of GH’s growth prospects is available in the InvestingPro Research Report, part of the platform’s coverage of 1,400+ US stocks.

In other recent news, Guardant Health reported impressive financial results for the second quarter of 2025. The company exceeded expectations with an earnings per share (EPS) of -$0.44, outperforming the anticipated -$0.72, which represents a 38.89% surprise. Revenue also surpassed forecasts, reaching $232.1 million compared to the expected $211.27 million, marking a 9.86% revenue surprise. As a result of these strong financial outcomes, Guardant Health’s management has raised their full-year revenue guidance to a growth rate of 24-25% year-over-year, up from the initial 15-16% projection. In light of these developments, Scotiabank (TSX:BNS) has increased its price target for Guardant Health to $60 from $57, while maintaining a Sector Outperform rating. These updates reflect the company’s robust performance and the positive reception from analysts.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.